Stem Cell Therapy International to merge with Histostem Korea
Stem Cell Therapy International Inc. (OTCBB: SCII) announced today that the Company has agreed to be a party to the settlement between Histostem, Incorporated, a Delaware Corporation (”Histostem USA”) and Histostem Corporation, a Korean Corporation (”Histostem Korea”). The agreement is contingent upon the close of the SCII and Histostem Korea merger, and specifically, the agreement is contingent …
[Read the full article here]Related News:
Stem Cell Therapy International, Inc. Announces Merger With Histostem and Launching of AmStem International, Inc.
Stem Cell Therapy Merges with Histostem, Launches AmStem …
Stem Cell Therapy International merges with Histostem